Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack-Reference-Cited by-同舟云学术

Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack

Published:2021-06-15 Issue:23 Volume:325 Page:2348
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Winner Paul K.¹²³⁴⁵,McAllister Peter⁶,Chakhava George⁷,Ailani Jessica⁸,Ettrup Anders⁹,Krog Josiassen Mette⁹,Lindsten Annika⁹,Mehta Lahar¹⁰,Cady Roger¹¹

Affiliation:

1. Palm Beach Headache Center, West Palm Beach, Florida

2. Neurology Research Institute Palm Beach, West Palm Beach, Florida

3. Premiere Research Institute, West Palm Beach, Florida

4. Palm Beach Neurology, West Palm Beach, Florida

5. Nova Southeastern University, Fort Lauderdale, Florida

6. New England Institute for Neurology and Headache, Stamford, Connecticut

7. D. Tvildiani Medical University, Multiprofile Clinic Consilium Medulla, Tbilisi, Georgia

8. Department of Neurology, Georgetown University Hospital, Washington, DC

9. H. Lundbeck A/S, Copenhagen, Denmark

10. Lundbeck Seattle BioPharmaceuticals Inc, Bothell, Washington

11. Lundbeck La Jolla Research Center, San Diego, California

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2781053/jama_winner_2021_oi_210054_1623359389.52675.pdf

Reference21 articles.

1. The International Classification of Headache Disorders, 3rd edition.;Headache Classification Committee of the International Headache Society;Cephalalgia,2018

2. A real-world analysis of patient characteristics, treatment patterns, and level of impairment in patients with migraine who are insufficient responders vs responders to acute treatment.;Lombard;Headache,2020

3. Migraine progression: a systematic review.;Buse;Headache,2019

4. From transformation to chronification of migraine: pathophysiological and clinical aspects.;Torres-Ferrús;J Headache Pain,2020

5. Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide.;Garcia-Martinez;J Pharmacol Exp Ther,2020

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unmet Needs in the Acute Treatment of Migraine;Advances in Therapy;2023-11-09

2. Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review;Therapeutics and Clinical Risk Management;2023-11

3. Gynecological trials frequently exclude people based on their symptoms rather than their condition: a systematic review of Cochrane reviews and their component trials;Journal of Clinical Epidemiology;2023-11

4. Pharmacokinetics and Safety of Eptinezumab in Healthy Chinese Participants: A Randomized Clinical Trial;Clinical Drug Investigation;2023-11

5. Headache and facial pain;Medicine;2023-09